Immunotherapy joins the fight against aggressive prostate cancer
NCT ID NCT03543189
Summary
This study is testing whether adding an immunotherapy drug called nivolumab to the standard treatment of radiation and hormone therapy is safe and more effective for men with a high-risk form of prostate cancer. The goal is to see if this combination can better control the cancer and delay its return. The trial involves 44 men and is focused on those with a specific, aggressive type of prostate cancer who are undergoing their first line of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.